Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

By sjmartinez • April 10, 2025

Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. PMID: 40207047; PMCID: PMC11979587.

Tags: abacavir, antiretroviral therapy, Infectious Diseases, major adverse cardiovascular events, Publications, REPRIEVE, Tenofovir

A Case of HIV-Associated Primary Central Nervous System Lymphoma Refractory to Methotrexate-Based Systemic Therapy and Immune Reconstitution

Cleveland JM, Cleveland HA, Chamberlain E, Sinclair J, Ku N, Schachter L, Di Carlo BA. A Case of HIV-Associated Primary Central Nervous System Lymphoma Refractory[...]

Coronary artery calcium and all-cause mortality in the Multicenter AIDS Cohort Study

Suzuki T, Haberlen S, Peterson TE, Palella F, Budoff MJ, Witt MD, Magnani JW, Post WS. Coronary artery calcium and all-cause mortality in the Multicenter[...]

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman[...]